ST Germain D J Co. Inc. Acquires New Stake in SPDR S&P Biotech ETF

ST Germain D J Co. Inc. recently established a new investment in the SPDR S&P Biotech ETF (NYSEARCA:XBI) during the fourth quarter of last year. According to reports, the company purchased 1,200 shares of this exchange-traded fund's stock, which is estimated to be worth around $108,000.

In addition to ST Germain D J Co. Inc., several other institutional investors and hedge funds have also been active in buying and selling shares of XBI. For instance, the Healthcare of Ontario Pension Plan Trust Fund significantly increased its stake in the SPDR S&P Biotech ETF by 198.6% during the third quarter. The trust fund now holds 9,229,000 shares valued at approximately $911,825,000 after purchasing an additional 6,138,000 shares in the previous quarter.

Another notable investment came from Clal Insurance Enterprises Holdings Ltd, which acquired a new stake in the SPDR S&P Biotech ETF during the third quarter worth about $141,284,000. Furthermore, Affinity Asset Advisors LLC enhanced its position in shares of the ETF by 105.4% during the second quarter, raising its total ownership to 37,550 shares valued at $3,481,000 after acquiring an additional 737,550 shares.

Additionally, Assetmark Inc. boosted its stake in the SPDR S&P Biotech ETF by an astonishing 72,653.0% during the third quarter, accumulating 589,299 shares now valued at $58,223,000 after purchasing an extra 588,489 shares during that period. Sivik Global Healthcare LLC also entered the market with a new position in the ETF valued at roughly $29,640,000.

SPDR S&P Biotech ETF Performance

As of the latest trading sessions, SPDR S&P Biotech ETF shares opened at $89.44. The ETF's 50-day moving average is currently at $95.48, while its 200-day moving average stands at $97.09. The market capitalization of the SPDR S&P Biotech ETF is around $6.82 billion, with a price-to-earnings ratio of 11.47 and a beta of 1.11. Over the past year, the ETF has experienced a low of $81.14 and a high of $105.47.

Understanding SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF aims to closely replicate the performance and attributes of the S&P Biotechnology Select Industry Index. This index represents the biotechnology segment within the broader S&P Total Markets Index, which tracks all common stocks listed across major U.S. stock exchanges.

More Information

For those interested in the latest movements of hedge funds with interests in XBI, resources such as financial advisory websites can provide updated 13F filings and insider trades for the SPDR S&P Biotech ETF.

ETF, Investment, Finance